> 首页 > 产品 > 一抗 > 基因重组 > Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab)

Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab)

Recombinant Antibody

Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%
The purity of Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab)is more than 100% ,determined by SEC-HPLC.
Immobilized human PD L1 His at 2 µg/mL can bind Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab)，EC50=0.005894 µg/mL
Human PD-L1 CHO-K cells were stained with Anti-B7-H1 / PD-L1 / CD274 Reference Antibody (atezolizumab) and negative control protein respectively, washed and then followed by PE and analyzed with FACS, EC263=1.533 nM
The endocytosis ratio atezolizumab by HCC827 increased with the increase of antibody concentration, and the Internalization Rate (%) reached 60% at antibody concentration of 0.5 nM.
Atezolizumab inhibited the tumor growth of MC38 on C57BL/6N mice. The result showed significant anti-tumor effects, with an tumor inhibition rate (TGI) of 85.2% at 2 mpk at D35.

产品详情
实验流程

Product Information
Application Applications Legend: E=ELISA WB=Western Blotting IHC=Immunohistochemistry IHC-P=Immunohistochemistry (Paraffin) IP=Immunoprecipitation IF=Immunofluorescence IC=Immunochemistry ICC=Immunocytochemistry FC=Flow Cytometry DB=Dot Blot	FC, Kinetics, Animal Model
Primary Accession	Q9NZQ7
Reactivity	Human
Clonality	Monoclonal
Isotype	IgG1
Calculated MW	33275 Da

Additional Information
Target/Specificity	B7-H1 / PD-L1 / CD274
Endotoxin	< 0.001EU/ µg,determined by LAL method.
Conjugation	Unconjugated
Expression system	CHO Cell
Format	Purified monoclonal antibody supplied in PBS, pH6.0, without preservative.This antibody is purified through a protein A column.

Protein Information
Name	CD274 (HGNC:17635)
Function	Plays a critical role in induction and maintenance of immune tolerance to self (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:31399419). As a ligand for the inhibitory receptor PDCD1/PD-1, modulates the activation threshold of T-cells and limits T-cell effector response (PubMed:11015443, PubMed:28813410, PubMed:28813417, PubMed:36727298). Through a yet unknown activating receptor, may costimulate T-cell subsets that predominantly produce interleukin-10 (IL10) (PubMed:10581077). Can also act as a transcription coactivator: in response to hypoxia, translocates into the nucleus via its interaction with phosphorylated STAT3 and promotes transcription of GSDMC, leading to pyroptosis (PubMed:32929201).
Cellular Location	Cell membrane; Single-pass type I membrane protein. Early endosome membrane; Single-pass type I membrane protein. Recycling endosome membrane; Single-pass type I membrane protein. Nucleus. Note=Associates with CMTM6 at recycling endosomes, where it is protected from being targeted for lysosomal degradation (PubMed:28813417). Translocates to the nucleus in response to hypoxia via its interaction with phosphorylated STAT3 (PubMed:32929201). [Isoform 2]: Endomembrane system; Single-pass type I membrane protein
Tissue Location	Highly expressed in the heart, skeletal muscle, placenta and lung. Weakly expressed in the thymus, spleen, kidney and liver. Expressed on activated T- and B-cells, dendritic cells, keratinocytes and monocytes.